All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Flare Therapeutics Inc. will receive $70 million in cash up front from Roche Holding AG, and the deal could ultimately bring the company about $1.8 billion plus royalties. Flare will search for small ...

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced ... Research & Development and Head of Boston Roche Innovation Center (BRIC), for ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

I am very excited about joining the company as an advisor to help bring this important ... His executive experience spans global industry leaders including Abbott Diagnostics, Roche Molecular ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Prothena (PRTA – Research Report), retaining the price target of ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

BeiGene is an emerging Chinese biotechnology company with a global leading position in hematologic ... an anti-TIGIT antibody, after Roche failed its TIGIT pivotal trial in July 2024. Hence, our ...